Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Hematologic Neoplasms 3Adenocarcinoma of Lung 3Cholangiocarcinoma 2Thyroid Carcinoma, Anaplastic 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Granuloma, Plasma Cell 1Glioblastoma 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 33fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 19Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Rituximab 14Tacrolimus 13Busulfan 12Vincristine 11Prednisone 11Methotrexate 11Filgrastim 11Doxorubicin 11Cyclosporine 11Radiotherapy 10Brentuximab Vedotin 10Antilymphocyte Serum 10Methylprednisolone 8Cytarabine 8Melphalan 7Cisplatin 6Ifosfamide 5Gemcitabine 5merphos 4ibritumomab tiuxetan 4Sirolimus 4Flow Cytometry 4Dexamethasone 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large-Cell, Anaplastic × ceritinib × Clear all
NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡